ATOPIC DERMATITIS · White paper
Atopic Dermatitis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About atopic dermatitis — and why its trials are hard
Atopic dermatitis (AD), or eczema, is a chronic, relapsing inflammatory skin disease marked by intense pruritus, dryness, and eczematous lesions, affecting up to about 20% of children and roughly 3% of adults. Its pathophysiology combines epidermal barrier dysfunction (notably filaggrin mutations) with type-2 immune dysregulation driven by IL-4 and IL-13. Therapy has been transformed by targeted biologics and small molecules: dupilumab (2017) validated IL-4/IL-13 blockade, tralokinumab (2021) targets IL-13, and oral JAK inhibitors upadacitinib and abrocitinib (both 2022) offer rapid itch and lesion control, alongside older topicals crisaborole, tacrolimus, and pimecrolimus. Trials are anchored by co-primary endpoints IGA 0/1 and EASI-75, with pruritus NRS and quality-of-life measures as key secondaries. Development challenges include subjective, variable severity scoring, high placebo response, difficult blinding of topicals, and fluctuating disease course. Failed or underperforming candidates such as tradipitant and montelukast underscore the need for validated endpoints and well-characterized moderate-to-severe populations.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Dupilumab (Dupixent) | 2017 | First biologic for moderate-to-severe AD; IL-4 receptor alpha (IL-4/IL-13) inhibitor | SOLO 1 & 2 (monotherapy) and CHRONOS (with topical corticosteroids) | IGA 0/1 and EASI-75 at week 16 | EASI-75 ~44-51% vs 12-15% placebo; IGA 0/1 ~36-38% vs ~9-10% placebo at week 16 |
| Abrocitinib (Cibinqo) | 2022 | Oral selective JAK1 inhibitor for moderate-to-severe AD | JADE MONO-1/-2 and JADE COMPARE | IGA 0/1 and EASI-75 at week 12 | EASI-75 up to ~62-68% (200 mg) vs 12-27% placebo at week 12 |
| Upadacitinib (Rinvoq) | 2022 | Oral selective JAK1 inhibitor for refractory moderate-to-severe AD (approved Jan 14, 2022) | Measure Up 1 & 2, AD Up | EASI-75 and IGA 0/1 at week 16 | EASI-75 ~70-80% vs ~13-16% placebo (unverified exact value) |
| Tralokinumab (Adbry) | 2021 | Biologic targeting IL-13 for moderate-to-severe AD (approved Dec 27, 2021) | ECZTRA 1, 2 & 3 | IGA 0/1 and EASI-75 at week 16 | EASI-75 ~25-33% monotherapy vs ~10-16% placebo at week 16 (unverified exact value) |
| Crisaborole (Eucrisa) | 2016 | Topical PDE-4 inhibitor for mild-to-moderate AD, ages 2 and older | AD-301 and AD-302 | ISGA clear/almost clear with ≥2-grade improvement at day 29 | 32.8% vs 25.4% and 31.4% vs 18.0% achieving ISGA success vs vehicle |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in atopic dermatitis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Tradipitant — EPIONE (NCT03568331) | Did not meet the primary endpoint of pruritus reduction in the overall population | Effect limited to mild disease; high placebo response and subjective itch endpoints |
| Montelukast — NCT00559546 | Ineffective for general AD symptom control | Leukotriene pathway not central to AD; better suited to asthma/rhinitis |
| Methotrexate — NCT00809172 | Less effective than cyclosporine in moderate-to-severe AD, though with a better safety profile | Slower onset and lower efficacy versus comparator immunosuppressant |
Choosing the right endpoint
Primary endpoints that matter in atopic dermatitis trials
- Investigator's Global Assessment (IGA 0/1) — FDA-preferred primary endpoint; proportion achieving clear/almost clear with a ≥2-grade improvement
- Eczema Area and Severity Index (EASI-75/EASI-90) — Proportion achieving ≥75%/90% improvement in EASI; a key co-primary/secondary efficacy measure
- Peak Pruritus NRS (≥4-point improvement) — Patient-reported itch endpoint; itch is among the most burdensome AD symptoms
- SCORAD and POEM — Composite clinician (SCORAD) and patient-reported (POEM) severity measures used as secondaries
- Quality-of-life instruments (DLQI/CDLQI) — Capture the broader life impact of AD, important for regulatory and payer value assessment
How iNGENū runs atopic dermatitis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Atopic Dermatitis clinical trials — FAQs
What are the newest FDA-approved treatments for atopic dermatitis?
What primary endpoints does the FDA expect in AD trials?
Why are atopic dermatitis trials difficult to run?
Ready to discuss your atopic dermatitis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal